Jan 12, 2026 10:14AM
Dec 8, 2025 08:32AM
Nov 7, 2025 09:00AM
Nov 7, 2025 09:00AM
Nov 6, 2025 04:14PM
Nov 6, 2025 01:55PM
Nov 6, 2025 01:54PM Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Aug 7, 2025 04:41PM
May 12, 2025 04:15PM
Mar 10, 2025 04:12PM
Dec 3, 2024 10:14AM
Aug 8, 2024 04:05PM
Jun 27, 2024 08:27AM
Jun 27, 2024 08:26AM Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
May 24, 2024 05:49AM
May 23, 2024 05:51PM
Mar 4, 2024 01:00AM
Jan 4, 2024 08:00AM
Dec 27, 2023 12:00PM
Dec 27, 2023 07:57AM
Dec 26, 2023 04:03PM Coherus (CHRS) Announces FDA Approval of UDENYCA ONBODY
Dec 7, 2023 05:55PM
Nov 28, 2023 11:17AM
Nov 28, 2023 11:16AM
Nov 6, 2023 04:07PM
Oct 27, 2023 03:10PM
Oct 27, 2023 03:07PM
Oct 5, 2023 08:53AM Coherus (CHRS) Announces Resubmission of BLA Supplement for UDENYCA ONBODY
Sep 27, 2023 09:10AM
Sep 25, 2023 08:32AM
Sep 8, 2023 09:05AM
Jul 20, 2023 04:04PM
Jun 16, 2023 07:05AM
Jun 1, 2023 08:35AM
Jun 1, 2023 08:33AM Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
Apr 27, 2023 08:05AM
Mar 6, 2023 04:01PM
Mar 6, 2023 08:01AM
Mar 6, 2023 08:00AM
Feb 15, 2023 08:26AM
Feb 15, 2023 08:25AM
Feb 13, 2023 08:25AM Coherus BioSciences (CHRS) Granted Permanent, Product-Specific Q-Code for CIMERLI
Feb 13, 2023 08:25AM
Jan 9, 2023 08:21AM
Jan 9, 2023 08:20AM
Jan 4, 2023 07:01AM
Dec 27, 2022 05:51AM
Dec 25, 2022 08:16AM
Dec 24, 2022 12:01AM Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Nov 8, 2022 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All